流感季或将提前！三价疫苗政采价持续走低，海外玩家“返场”，流感疫苗市场将如何变化？|传真

Group 1 - The flu season for 2025 is expected to be on par with pre-pandemic levels, with a notable increase in flu patients reported recently [1][5][6] - The dominant strain this year is A(H3N2), which has lower immunity in the population compared to last year's A(H1N1) strain [5][6] - Vaccination remains the most effective preventive measure, with a surge in vaccine demand observed in various regions [2][7] Group 2 - The price of trivalent flu vaccines has decreased significantly, reaching a low of 5.5 yuan per dose, while quadrivalent vaccines have maintained stable pricing [3][13] - Sanofi, a major overseas player, has resumed supply to the Chinese market after a 10-month hiatus, but this has not significantly impacted the domestic market dynamics [3][12] - Domestic vaccine manufacturers, such as Sinopharm, Beijing Kexing, and Hualan Biological, continue to dominate the market with a total of 322 batches of vaccines approved this year, compared to only 22 batches from Sanofi [12] Group 3 - The flu vaccine market is characterized by a growing demand, with experts indicating that the market is expanding rather than becoming more competitive due to the presence of Sanofi [12][14] - The pricing strategy for trivalent vaccines is shifting towards volume-based pricing, while quadrivalent vaccines are stabilizing after previous price wars [13][14] - The overall flu vaccine market is expected to differentiate between standard and premium products, catering to different consumer segments [14][15]